Latest News

On January 25th 2023 the VACCELERATE team from Cyprus joined a EUPATI (https://www.eupati.eu/) meeting to support and enhance the role of patient advocacy groups in vaccine clinical research. They provided a gift with the VACCELERATE educational cards.

Do you have 10 minutes to help us prepare for the next COVID19 vaccine? Complete this anonymous online survey to help researchers better understand willingness to participate in vaccine clinicaltrials: https://apps.cleoresearch.org/surveys/?s=EKRJADCNX49AFDRK

Current Project: VACCELERATE Survey on the frequency of viral respiratory diseases in Germany

COVID-19? RSV infection? Or influenza? With the cold season, the number of respiratory diseases increases again. We are currently conducting a survey to determine the frequency and distribution of respiratory diseases.

For this purpose, volunteers from our Volunteer Registry are contacted and receive a test kit from us.

The test can detect 5 different viruses and is used if one or more of the following symptoms are present for at least 24 hours: Cough, sore throat, runny nose, difficulty breathing, redness of the eyes, loss of smell or taste and also aching limbs with or without fever.

The test result is reported to the VACCELERATE team by email and evaluated.

 

Aktuelles Projekt: VACCELERATE Erhebung zur Häufigkeit von viralen Atemwegserkrankungen in Deutschland

COVID-19? RSV Infektion? Oder doch Influenza? Mit der kalten Jahreszeit steigt auch die Anzahl von Atemwegserkrankungen wieder an. Aktuell führen wir eine Untersuchung durch, um die Häufigkeit und Verteilung dieser Atemwegserkrankungen in Deutschland festzustellen.

Dazu schreiben wir bei uns registrierte Teilnehmerinnen und Teilnehmer an und senden Interessierten ein Test-Kit zu.

Der Test kann 5 verschiedene Viren nachweisen und sollte durchgeführt werden, wenn für mindestens 24 Stunden Symptome bestehen wie Husten, Halsschmerzen, Schnupfen, Atembeschwerden, Augenrötung, Geruchs- oder Geschmacksverlust oder Gliederschmerzen mit oder ohne Fieber.

Das Testergebnis wird dann dem VACCELERATE Team per E-Mail mitgeteilt und ausgewertet.

New Scientific VACCELERATE Publication

08.10.2022 / A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network (Trials): https://trebuchet.public.springernature.app/get_content/29c30f05-5202-4419-a257-e7f84bd41444

Upcoming VACCELERATE Webinar

March 6 2023, 13.00-14.00 (CET), Vaccine Confidence Survey 2022 in the EU

NEW VACCELERATE PUBLICATION

31.08.2022 / Vaccination rates in Europe are not associated with online media intensity (JCOM Journal of Science Communication): https://jcom.sissa.it/archive/21/05/JCOM_2105_2022_A05

VACCELERATE Press Release:

First children participate in UMC Utrecht-led study:
Is one COVID-19 vaccination dose enough for kids?

VACCELERATE Press Release: 

How many COVID-19 infections are there in Germany? Pilot study in Cologne investigates high dark figure

EU-COVAT-1 AGED Study progress in Norway

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed non risus. Suspendisse lectus tortor, dignissim sit amet, adipiscing nec, ultricies sed, dolor.

NEW VACCELERATE PUBLICATION: 

02.06.2022 / VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment (ScienceDirect): https://www.sciencedirect.com/science/article/pii/S0264410X22006053?via%3Dihub

EU-COVAT-2 BOOSTAVAC study start in Ireland

Ecraid begins its fight against infectious diseases. VACCELERATE is happy to support the project with an online Study Nurse Training Course & Certificate.